New LC–UV methods for pharmaceutical analysis of novel anti-diabetic combinations

Abstract

New, simple, selective, and sensitive liquid chromatography–ultraviolet (LC–UV) methods have been developed and subsequently validated for simultaneous determination of linagliptin–empagliflozin combination and simultaneous determination of alogliptin benzoate–pioglitazone hydrochloride combination. Linearity was found to be acceptable over the concentration ranges of 2–50 μg mL −1 , 4–100 μg mL −1 , 0.5–25 μg mL −1 , and 1–25 μg mL −1 for linagliptin (LNG), empagliflozin (EMG), alogliptin (ALG), and pioglitazone (PGN), respectively. All the methods were applied successfully to the analysis of the pharmaceutical dosage forms. The optimized methods were validated and proved to be robust and accurate for the quality control of the mentioned drugs in their different pharmaceutical dosage forms.